This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mannkind Founder Loses Cult Status

A more likely timeline is Afrezza two years away from another FDA approval decision, perhaps more. Call it 2013, and that's assuming the two new Afrezza studies yield positive results. Longer delays could be in the cards if the new Dreamboat device underperforms the older MedTone device. And what if FDA still has issues or concerns with Afrezza's safety or efficacy regardless of the device used to deliver it? Conceivably, FDA could have approved Afrezza based on the phase III data generated by the older MedTone device. The agency didn't do that, a fact MannKind hasn't adequately explained.

Mann might be rich but he can't bankroll MannKind forever. At the end of the third quarter, Mannkind had $98 million in cash and a credit line of around $100 million. An equity funding arrangement with Seaside, which the company has used recently to bring in more cash, is turned off with the stock trading below $6.50 a share. The company also carries about $460 million in debt.

At its current rate of spending, MannKind runs out of money in the third quarter. If spending ramps higher due to these two new clinical trials, MannKind could be forced into a series of highly dilutive stock offerings to keep the lights on. After all the setbacks and losses, Mann is going to need more than bravado and resume of past business successess to convince any sensible investor that Afrezza has a golden future.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNKD $0.97 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs